Bacteroides fragilis as Next Generation Probiotics
Background B. fragilis and Diseases Highlights Products FAQs Resources
Aided by our rich experience and professional scientists, Creative Biolabs has completed a series of challenges in the past years. In particular, we have established an advanced Bacteroides fragilis platform which enables us to offer a series of high-quality services for our worldwide customers. Meanwhile, our scientists specialized in live biotherapeutics drug discovery will work with you to develop the most appropriate strategy that will offer the most meaningful data for your research.
Background of Bacteroides fragilis
Bacteroides fragilis belongs to the family Bacteroidaceae. It is a Gram-negative bacterium that is strongly associated with peritoneal infections and is the main cause of bacteremia and malignant tumors in humans. Pilot studies have shown that it is a common type of microorganism in humans and is usually symbiotic. Meanwhile, many studies have also revealed that Bacteroides fragilis can lead to different levels of infections when the tissue barrier is broken during surgery or trauma. Moreover, recent researchers have indicated that Bacteroides fragilis outer-membrane vesicles (OMVs) have been considered as a suitable delivery system for the transportation of biochemical substances. Also, several strains of Bacteroides fragilis, such as enterotoxigenic Bacteroides fragilis (ETBF) strain, have been isolated from different human colon samples. The data have suggested that these strains play an important role in various human diseases.
Fig.1 A single strain of Bacteroides fragilis protects gut integrity and reduces GVHD.1
Bacteroides fragilis and Diseases
Bacteroides fragilis has proven its essential role as a friendly commensal in humans. The data have demonstrated that Bacteroides fragilis can regulate the expression level of bradykinin in humans, suggesting it could be a next-generation probiotics (NGPs) for treating thrombotic diseases. Furthermore, many reports have shown that ETBF strains of Bacteroides fragilis can produce specific enterotoxin and may be beneficial to the treatment of diseases. As a result, a variety of Bacteroides fragilis -based and Bacteroides fragilis -targeted therapies have been generated for designing modified live biotherapeutics targeting a wide spectrum of clinical applications. Nowadays, Creative Biolabs has established a comprehensive next-generation probiotics (NGPs) discovery platform based on Bacteroides fragilis for developing novel live biotherapeutics drugs for the treatment of diseases, including but not limited to:
|
Diseases
|
Functions of Bacteroides fragilis
|
|
Inflammatory Bowel Disease
|
Inflammatory bowel disease (IBD) is a class of inflammatory diseases that often involves long-term inflammation of the digestive tract. Till now, many kinds of IBD, such as Crohn's disease, have been broadly studied, and the results have illustrated that the dysfunction of the immune system should be the main cause of human IBD. In the past few years, anti-inflammatory drugs, such as mesalamine, and sulfasalazine, have been used as standard therapy for IBD. Recently, since the ETBF strain has been isolated from patients with IBD, Bacteroides fragilis has been regarded as a perfect NGP candidate in the clinic.
|
|
Colorectal Cancer
|
Evidence has shown that Bacteroides fragilis can play a protecting role in treating colorectal cancer (CRC) by mediating immune responses and regulating the level of epithelial cells. Meanwhile, Bacteroides fragilis can prevent the expression of specific chemokine receptors (CCR5) and produce polysaccharide A against CRC in mice models. Therefore, Bacteroides fragilis has been used to inhibit CRX-associated tumorigenesis and tumor formation and may provide a unique therapeutic opportunity for CRC treatment.
|
Highlights of Our Bacteroides fragilis Drug Discovery Services
-
One-stop Bacteroides fragilis solution
-
Excellent expert team
-
Numerous state-of-the-art instruments
-
Timely data feedback
-
Cost-effective service manner
As a global CRO company, Creative Biolabs is well-equipped to handle almost any project of Bacteroides fragilis - based haptens regardless of scope or complexity. We have integrated the key components of early development to ensure that programs advance while meeting any special requirement with the flexibility to address dynamic challenges. For more information, please feel free to contact us or send us an inquiry.
Related Products
|
CAT
|
PRODUCT NAME
|
PRODUCT OVERVIEW
|
|
LBST-013FG
|
Bacteroides fragilis
|
Bacteroides fragilis was isolated from appendix abscess. It is an anaerobic, Gram-negative, pleomorphic to rod-shaped bacterium.
|
|
LBST-014FG
|
Bacteroides fragilis; 37758
|
Bacteroides fragilis was isolated from human blood. It is an anaerobic, Gram-negative, pleomorphic to rod-shaped bacterium.
|
|
LBST-015FG
|
Bacteroides fragilis; 36926
|
Bacteroides fragilis was isolated from human blood. It is an anaerobic, Gram-negative, pleomorphic to rod-shaped bacterium.
|
|
LBST-016FG
|
Bacteroides fragilis; 36902
|
Bacteroides fragilis was isolated from human perianal abscesses. It is an anaerobic, Gram-negative, pleomorphic to rod-shaped bacterium.
|
|
LBST-017FG
|
Bacteroides fragilis; 35671
|
Bacteroides fragilis was isolated from the human tube. It is an anaerobic, Gram-negative, pleomorphic to the rod-shaped bacterium.
|
|
LBST-018FG
|
Bacteroides fragilis; 25931
|
Bacteroides fragilis was isolated from human pleural fluid. It is an anaerobic, Gram-negative, pleomorphic to rod-shaped bacterium.
|
|
LBST-019FG
|
Bacteroides fragilis; 49424
|
Bacteroides fragilis was isolated from human blood. It is an anaerobic, Gram-negative, pleomorphic to rod-shaped bacterium.
|
|
LBST-020FG
|
Bacteroides fragilis
|
Bacteroides fragilis was isolated from sewage water. It is an anaerobic, Gram-negative, pleomorphic to rod-shaped bacterium.
|
|
LBST-021FG
|
Bacteroides fragilis; 20793-3
|
Bacteroides fragilis was isolated from infants with diarrhea. It is an anaerobic, Gram-negative, pleomorphic to rod-shaped bacterium.
|
|
LBST-022FG
|
Bacteroides fragilis; 23745
|
Bacteroides fragilis was isolated from pleural fluid. It is an anaerobic, Gram-negative, pleomorphic to rod-shaped bacterium.
|
Frequently Asked Questions
What makes B. fragilis stand out as a next-generation probiotic?
B. fragilis is gaining attention for its unique ability to modulate the immune system, promote gut health, and potentially address various diseases. Unlike traditional probiotics, it possesses sophisticated mechanisms to interact with the host, offering promising avenues for therapeutic development.
How does B. fragilis contribute to gut health?
B. fragilis plays a crucial role in maintaining gut homeostasis by producing short-chain fatty acids (SCFAs), promoting epithelial barrier integrity, and modulating immune responses. Its presence in the gut microbiome is associated with reduced inflammation and improved overall digestive function.
What services and products does Creative Biolabs offer for B. fragilis probiotic discovery?
Creative Biolabs provides comprehensive services for B. fragilis probiotic discovery, including strain isolation, characterization, and functional analysis. Additionally, we offer a range of B. fragilis probiotic strains and products tailored for research use, facilitating investigations into their therapeutic potential.
Resources
References
-
Sofi, M. Hanief, et al. "A single strain of Bacteroides fragilis protects gut integrity and reduces GVHD." Jci Insight 6.3 (2021).
-
Distributed Under Open Access license CC BY 4.0, without modification.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
